Methotrexate-related lymphoproliferative disorder with extensive vascular involvement in a patient with rheumatoid arthritis

Shimura, Chieko; Satoh, Takahiro; Takayama, Kaoru; Yokozeki, Hiroo

doi:10.1016/j.jaad.2008.10.051

Cited by 16 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 12 cases of MTX-LPD with mucocutaneous ulcer reported in the literature 7,10,11,12,13,14,15,16,17 all except 1 17 were EBV-positive and all 9 cases with available data showed complete remission without chemotherapy. Most of our patients with positive outcomes had been diagnosed with EBVMCU.…”

Section: Discussionmentioning

confidence: 95%

A Clinical, Pathological, and Genetic Characterization of Methotrexate-associated Lymphoproliferative Disorders

Yamakawa

Fujimoto²,

Kawabata³

et al. 2013

J Rheumatol

113

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

A Clinical, Pathological, and Genetic Characterization of Methotrexate-associated Lymphoproliferative Disorders

Yamakawa

Fujimoto²,

Kawabata³

et al. 2013

J Rheumatol

113

View full text Add to dashboard Cite

show abstract

“…The patient of the present case was EBV negative, but LPD regressed with the cessation of MTX. There is one case report of RA with MTX-LPD that presented with vascular involvement (10). However, in that case, polymorphic or Hodgkin-like LPD with EBER-positive large B-cells in the destructed arteries and veins and extensive infiltration into the subcutaneous tissue.…”

Section: Discussionmentioning

confidence: 97%

Methotrexate-associated Intravascular Large B-cell Lymphoma in a Patient with Rheumatoid Arthritis

et al. 2016

View full text Add to dashboard Cite

Intravascular large B-cell lymphoma (IVLBCL) is a rare and clinically aggressive lymphoma with an unfavorable prognosis. We report the case of a 50-year-old woman who was diagnosed with IVLBCL during treatment with methotrexate (MTX) and biologic agents for rheumatoid arthritis. The symptoms showed partial improvement only after the cessation of both treatments. She subsequently received chemotherapy and achieved a complete remission and has remained free of recurrence for 2 years without any further treatment. We herein describe a rare case of IVLBCL which presented with the features of an MTX-associated lymphoproliferative disorder.

show abstract

“…Thus, it mainly prevents de novo pyrimidine and purine syntheses (Celtikci et al, 2009;Patiño-García et al, 2009;Shimura et al, 2009). It has been reported that MTX efficiently suppresses PIA when given after the onset of arthritis, but the mechanism remains obscure (Lange et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

Methotrexate ameliorates pristane-induced arthritis by decreasing IFN-γ and IL-17A expressions

Hou

Meng

Zheng

et al. 2011

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: This study was carried out to test the effects of methotrexate (MTX) and black seed oil (BSO) on pristane-induced arthritis (PIA) in rats. Methods: Inbred dark agouti (DA) rats were induced by a single subcutaneous injection of pristane, and then treated with MTX or BSO. Arthritis severity was evaluated macroscopically and microscopically. Plasma nitric oxide (NO) concentration was determined by the Griess method and cytokine mRNA expression in the spleen was detected by the real-time reverse transcription-polymerase chain reaction (RT-PCR). Results: The clinical arthritis severity was decreased after MTX treatment, while the BSO groups did not show significant changes compared with the disease group. The plasma NO level of the MTX group was significantly decreased compared with the disease group, but the BSO groups showed no difference from the disease group in plasma NO levels. The interferon-γ (IFN-γ) and interleukin-17A (IL-17A) mRNA expressions in the spleens were significantly decreased in the MTX group, but only showed a declining trend in the BSO groups compared with the disease group. Neither MTX nor BSO had an effect on the mRNA expressions of IL-4, transforming growth factor β (TGF-β), and tumor necrosis factor-α (TNF-α) in the spleen. Conclusions: MTX, but not BSO, can reduce the arthritis severity and decrease the mRNA expressions of IFN-γ and IL-17A in pristane-induced arthritis of rats.

show abstract

Methotrexate-related lymphoproliferative disorder with extensive vascular involvement in a patient with rheumatoid arthritis

Cited by 16 publications

References 25 publications

A Clinical, Pathological, and Genetic Characterization of Methotrexate-associated Lymphoproliferative Disorders

A Clinical, Pathological, and Genetic Characterization of Methotrexate-associated Lymphoproliferative Disorders

Methotrexate-associated Intravascular Large B-cell Lymphoma in a Patient with Rheumatoid Arthritis

Methotrexate ameliorates pristane-induced arthritis by decreasing IFN-γ and IL-17A expressions

Contact Info

Product

Resources

About